Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Oral presentation for TPST-1120 completed Phase 1 trial resultsPoster presentation for TPST-1495 trial in progress SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest...
-
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing novel therapeutics that combine both targeted...
-
Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in tumorsAdditional data further supporting and differentiating TPST-1495, a clinical-stage dual...
-
First clinical data presentation planned for ASCO: TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization armsTPST-1120 randomized study in first-line HCC patients with partner...
-
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
-
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
-
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
-
Combination based on both strong mechanistic rationale and preclinical data SOUTH SAN FRANCISCO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage...
-
Data Reported at the 2021 Society for Immunotherapy of Cancer Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...
-
First patients dosed in first line, randomized, global Phase 1b/2 hepatocellular carcinoma (“HCC”) study of TPST-1120 combination regimen, in collaboration with F. Hoffmann La RocheExclusive rights to...